natgillin/translations-raw huggingface dataset:
Unwanted effects to the kidney have been reported.
Poročali so o neželenih učinkih na ledvice.
These include changes to your urine, increased level of creatinine in your blood, and back pain caused by kidney problems, including kidney failure and damage to kidney tubule cells.
Med njimi so spremembe v urinu, zvišana raven kreatinina v krvi in bolečina v hrbtu zaradi bolezni ledvic, vključno z ledvično odpovedjo in poškodbami celic v ledvičnih tubulih.
Your doctor may do blood tests to see if your kidneys are working properly.
Zdravnik bo morda opravil krvne preiskave, da preveri delovanje ledvic.
You may also experience inflammation of the kidney, passing a lot of urine and feeling thirsty.
Morda boste imeli tudi vnetje ledvic, povečano izločanje urina in občutek žeje.
Breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may also occur in patients who develop damage to the kidney tubule cells.
55 Pri bolnikih, pri katerih pride do poškodb tubularnih celic ledvic, se lahko pojavijo tudi razkrajanje mišičja, mehčanje kosti (z bolečinami v kosteh in včasih posledičnimi zlomi), bolečine v mišicah, mišična šibkost in zmanjšanje količine kalija ali fosfata v krvi.
Psychiatric side effects in addition to those listed above include delusions (false beliefs), neurosis, psychosis (personality changes).
Psihiatrični neželeni učinki poleg zgoraj naštetih vključujejo blodnje (napačna prepričanja), nevrozo in psihozo (spremembo osebnosti).
These problems tend to occur more often in those who have a history of mental illness.
Te težave so navadno pogostejše pri tistih, ki so predhodno imeli duševno bolezen.
Always notify your doctor immediately if you have these symptoms.
Vedno takoj obvestite zdravnika, če se pojavijo ti simptomi.
Other unwanted effects include: itchy rash to the skin caused by a reaction to sunlight, shortness of breath, fatty liver, disturbances of coordination and balance.
Med drugimi neželenimi učinki so srbeč izpuščaj na koži, ki je posledica reakcije na sonce, kratka sapa, zamaščena jetra ter motnje koordinacije in ravnotežja.
Combination antiretroviral therapy (such as Atripla) may change your body shape, by changing the way body fat is distributed.
Kombinirano protiretrovirusno zdravljenje (kot je zdravljenje z zdravilom Atripla) lahko povzroči spremembo oblike telesa zaradi spremembe porazdelitve maščob v telesu.
You may lose fat from your legs, arms and face; gain fat around the abdomen (tummy) and internal organs; get larger breasts or fatty lumps on the back of the neck (‘ buffalo hump’).
Lahko izgubite maščobe v nogah, rokah in obrazu ter jih pridobite okoli trebuha (trebušček) in notranjih organov; lahko se vam povečajo prsi ali pa se nakopiči maščoba na zadnji strani vratu (» bivolja grba «).
The cause and the long-term effects of these changes are not yet known.
Vzrok za te spremembe in njihovi dolgoročni učinki niso znani.
Combination antiretroviral therapy may also cause increased fat levels in the blood (hyperlipaemia) and resistance to insulin.
Kombinirano protiretrovirusno zdravljenje lahko povzroči tudi zvišanje ravni maščob v krvi (hiperlipidemija) in odpornost na insulin.
Your doctor will test for these changes.
Zdravnik bo opravil preiskave, s katerimi bo ugotovil, ali so se pojavile te spremembe.
HOW TO STORE ATRIPLA
SHRANJEVANJE ZDRAVILA ATRIPLA
Do not use Atripla after the expiry date which is stated on the bottle label and carton after {EXP}.
Zdravila Atripla ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na steklenički in na škatli poleg oznake » Exp «.
What Atripla contains
Kaj vsebuje zdravilo Atripla
- The active substances are efavirenz, emtricitabine and tenofovir disoproxil.
- Zdravilne učinkovine so efavirenz, emtricitabin in tenofovirdizoproksil.
Each Atripla
Ena filmsko obložena
film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate).
tableta zdravila Atripla vsebuje 600 mg efavirenza, 200 mg emtricitabina in 245 mg tenofovirdizoproksila (v obliki fumarata).
- The other ingredients in the tablet are croscarmellose sodium, hydroxypropylcellulose,
- Pomožne snovi v tableti so natrijev karmezolat, hidroksipropilceluloza, magnezijev stearat,
- The other ingredients in the tablet film coating are iron oxide black, iron oxide red,
mikrokristalna celuloza, natrijev lavrilsulfat.
macrogol 3350, poly(vinyl alcohol), talc, titanium dioxide.
- Pomožne snovi v filmski oblogi tablete so črni železov oksid, rdeči železov oksid, makrogol 3350,
What Atripla looks like and contents of the pack
polivinilalkohol, smukec, titanov dioksid.
Atripla film-coated tablets are pink, capsule shaped tablets, engraved on one side with the number “ 123” and plain on the other side.
Atripla filmsko obložene tablete so rožnate barve, v obliki kapsule, z vtisnjeno oznako » 123 « na eni strani in brez oznake na drugi strani.
Atripla comes in bottles of 30 tablets (with a silica gel sachet that must be kept in the bottle to help protect your tablets).
Zdravilo Atripla je na voljo v stekleničkah po 30 tablet (z vrečko s silikagelom, ki jo morate hraniti v steklenički za zaščito tablet).
Gilead Sciences Limited IDA Business & Technology Park Carrigtohill County Cork Ireland
Gilead Sciences Limited IDA Business & Technology Park Carrigtohill County Cork Irska
Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
57 Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1849
This leaflet was last approved in
58 Navodilo je bilo odobreno
ATryn is a white powder to be made up into a solution for infusion (drip into a vein), containing the active substance antithrombin alfa.
Vsebuje zdravilno učinkovino antitrombin alfa.
What is ATryn used for?
Za kaj se zdravilo ATryn uporablja Zdravilo ATryn se uporablja pri operacijah bolnikov s prirojenim pomanjkanjem antitrombina.
ATryn is used in patients who have an inherited reduction of the protein antithrombin (congenital antithrombin deficiency), when they undergo surgery, to prevent problems due to the formation of clots in the vessels (thromboembolism).
Z zdravilom ATryn preprečimo težave zaradi nastajanja strdkov v žilju (tromboembolija).
ATryn is normally given with heparin (another anti-clotting medicine).
Zdravilo ATryn se običajno daje s heparinom (drugim zdravilom proti strjevanju krvi).
The aim is to restore, for the time when the patient is at risk, a level of antithrombin activity that is normal.
Cilj zdravljenja je, da v času, ko je bolnik v nevarnosti, aktivnost antitrombina vzpostavi na normalno raven.
The doctor needs to calculate the doses to use, based both on the patient’ s weight and the patient’ s level of antithrombin activity.
Zdravnik mora izračunati uporabljeni odmerek na osnovi telesne mase bolnika in ravni aktivnosti antitrombina pri bolniku.
The medicine is given as an infusion.
Zdravilo se daje z infuzijo.
The first infusion lasts 15 minutes (loading dose), and it is then followed by a continuous infusion.
Prva infuzija traja 15 minut (začetni odmerek), sledi pa ji neprekinjena infuzija.
The patients should be continually monitored to adjust the infusion rate so that their antithrombin activity is at least 80% of the normal level for the duration of the treatment.
Bolnike je treba stalno spremljati zaradi prilagajanja hitrosti infundiranja tako, da aktivnost antitrombina med zdravljenjem znaša najmanj 80% normalne ravni.
See the Package Leaflet for the full instructions on calculating and adjusting the doses.
Za celovita navodila o izračunu in prilagajanju odmerkov glejte Navodilo za uporabo.
ATryn is an anti-clotting agent.
Zdravilo ATryn je sredstvo proti strjevanju krvi.
The active substance in ATryn, antithrombin alfa, is a copy of the natural blood protein that is produced by recombinant DNA technology.
Zdravilna učinkovina zdravila ATryn, antitrombin alfa, je kopija naravne beljakovine v krvi, ki je izdelana s tehnologijo rekombinantne DNA.
It is extracted from the milk of goats that have had a gene (DNA) inserted, which makes them able to produce the human protein in their milk.
Pridobljen je iz kozjega mleka, v katerega so vstavili gen (DNA), ki omogoča tvorbo človeške beljakovine v kozjem mleku.
In the body, antithrombin blocks thrombin, one of the substances involved in blood coagulation (clotting).
V telesu antitrombin blokira trombin, eno od snovi, ki sodelujejo pri koagulaciji (strjevanju) krvi.
Thrombin plays a central role in the process of blood clotting.
Trombin ima osrednjo vlogo pri strjevanju krvi.
Patients who have a congenital antithrombin deficiency have blood levels of antithrombin that are lower than normal, which may result in a reduced anti-clotting capacity of the blood.
Pri bolnikih, ki imajo prirojeno pomanjkanje antitrombina, so ravni antitrombina v krvi nižje od običajnih, kar lahko povzroči manjšo zmožnost preprečevanja strjevanja krvi.
This increases the risk of the formation of clots during high-risk situations.
S tem se poveča nevarnost tvorbe strdkov v nevarnejših situacijah.
ATryn corrects the antithrombin deficiency, and gives temporary control of the clotting disorder.
Zdravilo ATryn odpravi pomanjkanje antitrombina in nudi začasni nadzor nad motnjo strjevanja krvi.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged How has ATryn been studied?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Kako je bilo zdravilo ATryn raziskano?
The effects of ATryn were first tested in experimental models before being studied in humans.
Učinki zdravila ATryn so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
One study was carried out in 14 patients aged from 21 to 74 years of age, with congenital antithrombin deficiency and at risk of a thromboembolic event (surgery [5 patients] or childbirth [9 patients]).
Opravljena je bila ena študija in sicer na 14 bolnikih, starih od 21 do 74 let, ki so imeli prirojeno pomanjkanje antitrombina in bili v nevarnosti za tromboembolični dogodek (operacija [5 bolnikov] oz. porod [9 bolnic]).
The studies measured how many patients developed DVT (deep vein thrombosis: formation of a clot in the vessels of the leg) up to 30 days after treatment.
V študiji so merili, pri koliko bolnikih se je pojavila globoka venska tromboza (tvorba strdkov v žilju nog) v 30 dneh po zdravljenju.
The condition is rare (it is estimated that about one person in 3,000 to 5,000 has a congenital antithrombin deficiency), and this explains why few patients have been treated during the study.
Bolezen je redka (ocenjeno je, da ima prirojeno pomanjkanje antitrombina ena oseba izmed 3000 do 5000), zato je bilo v študiji zdravljenih tako malo bolnikov.
What benefit has ATryn shown during the studies?
Kakšne koristi je zdravilo ATryn izkazalo med raziskavami?
In the study, among the 13 patients in whom the effectiveness of the treatment could be assessed, 2 had an episode of DVT, of which only one needed treatment.
V študiji so lahko učinkovitost zdravljenja ocenili pri 13 bolnikih, od katerih sta 2 imela epizodo globoke venske tromboze, le eden izmed teh dveh pa je potreboval zdravljenje.
In addition, when ATryn was used in 5 patients who received the medicine during surgery in a ‘ compassionate use programme’ (when a Company makes available to doctors a medicine before it is fully licensed to treat a specific patient who needs it), no thromboembolism was seen.
Pri njih niso odkrili tromboembolije.
The results taken together support the effectiveness of ATryn in preventing thromboembolism in such patients.
Vsi rezultati skupaj potrjujejo učinkovitost zdravila ATryn za preprečevanje tromboembolije pri teh bolnikih.
During the studies of ATryn, the most common side effects (seen in between 1 and 10 patients in 100) were dizziness, headache, haemorrhage (bleeding, including bleeding at the site of the injection, or bleeding after surgery), nausea (feeling sick), and wound secretion (discharge at the site of the surgical cut).
V študijah zdravila ATRyn so bili najpogostejši neželeni učinki (opaženi pri 1 do 10 bolnikih od 100) omotica, glavobol, hemoragija (krvavitev, vključno s krvavitvijo na mestu injiciranja ali krvavitev po operaciji), navzeja (slabost) in izcedek iz rane (izločki na mestu kirurškega reza).
For the full list of all side effects reported with ATryn, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila ATryn, glejte Navodilo za uporabo.
Because ATryn is a protein given by injection, patients can develop antibodies (when the body makes special proteins against the medicine), with a risk of an allergic reaction at the time of injection.
Ker je zdravilo ATryn beljakovina, ki se daje z injekcijo, lahko bolniki razvijejo protitelesa (v telesu začnejo nastajati posebne beljakovine proti zdravilu), pri čemer pa obstaja tveganje za alergijsko reakcijo v času injiciranja.
However, until now this has not been seen in patients treated with ATryn.
Vendar do sedaj tega pri bolnikih, zdravljenih z zdravilom ATryn, niso opazili.
ATryn should not be used in people who may be hypersensitive (allergic) to any of the ingredients, or to goat or goat milk.
Zdravila ATryn se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) katero koli sestavino zdravila ali na koze oziroma kozje mleko.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the data provided by the Company have shown that, used at a dose that is calculated as recommended, ATryn, can bring the antithrombin activity levels to an acceptable level in non-pregnant patients with congenital antithrombin deficiency undergoing surgery.
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da podatki, ki jih je predložilo podjetje, kažejo, da lahko zdravilo ATryn v odmerku, ki je izračunan po priporočenem postopku, zviša ravni aktivnosti antitrombina na sprejemljivo raven pri nenosečih bolnikih s prirojenim pomanjkanjem antitrombina, ki morajo prestati operacijo.
They decided that ATryn’ s benefits are greater than its risks, and recommended that ATryn be given marketing authorisation.
Odbor je mnenja, da so koristi zdravila ATryn večje od z njim povezanih tveganj, zato je priporočil odobritev dovoljenja za promet z zdravilom ATryn.
ATryn has been authorised under “ Exceptional Circumstances”.
Zdravilo ATryn je bilo odobreno „ v izjemnih okoliščinah “.
This means that because the disease is rare, it has not been possible to obtain complete information about ATryn.
To pomeni, da zaradi redkosti bolezni o zdravilu ATryn še ni bilo mogoče dobiti celovitih podatkov.
Every year, the EMEA will review any new information that may become available and this summary will be updated as necessary.
Evropska agencija za zdravila (EMEA) bo vsako leto pregledala vse razpoložljive nove informacije in po potrebi posodobila ta povzetek.
The company that makes ATryn will complete a study currently ongoing to look in particular at the use of ATryn at the time of childbirth in pregnant women with congenital antithrombin deficiency.
Podjetje, ki izdeluje zdravilo ATryn, bo končalo študijo, ki trenutno poteka in s katero preučujejo uporabo zdravila ATryn med porodom pri nosečnicah s prirojenim pomanjkanjem antitrombina.
They will also put in place, before launch, programmes to ensure that doctors can report on the patients they treat, especially to monitor the development of antibodies against ATryn.
Preden bo podjetje dalo zdravilo na trg, bodo vzpostavljeni programi, ki bodo zdravnikom omogočali, da poročajo o bolnikih, ki jih zdravijo, in zlasti da spremljajo nastajanje protiteles proti zdravilu ATryn.
Which measures are being taken to ensure the safe use of ATryn?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila ATryn?
Once the medicine is on the market, the company that makes ATryn will closely monitor its safety, looking in particular at the development of antibodies.
Ko bo zdravilo na trgu, bo podjetje, ki izdeluje zdravilo ATryn, natančno spremljalo varnost zdravila, zlasti razvoj protiteles.
The European Commission granted a marketing authorisation valid throughout the European Union for ATryn on 28 July 2006.
Evropska komisija je dovoljenje za promet z zdravilom ATryn, veljavno po vsej Evropski uniji, odobrila dne 28. julija 2006.
The marketing authorisation holder is LEO Pharma A/ S.
Imetnik dovoljenja za promet z zdravilom je družba LEO Pharma A/ S.
The full EPAR for ATryn can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo ATryn je na voljo tukaj
This summary was last updated in 08-2007.
Povzetek je bil nazadnje posodobljen 08- 2007.
EU/ 1/ 06/ 355/ 001
Številka EU EU/ 1/ 06/ 355/ 001
ATryn
Izmišljeno ime ATryn
1750 IU
jakost 1750 IE
Powder for solution for infusion
farmacevtska oblika Prašek za raztopino za infundiranje
Intravenous use
pot uporabe Intravenska uporaba
vial (glass)
ovojnina Viala (steklena)
vial (glass)
Viala (steklena)
ATryn 1750 IU powder for solution for infusion
ATryn 1. 750 i. e. prašek za raztopino za infundiranje
ATryn is presented as a powder for solution for infusion containing nominally 1750 IU antithrombin alfa per vial.
ATryn je na razpolago v obliki praška za pripravo raztopine za infundiranje, ki vsebuje nominalno 1750 i. e. antitrombina alfa na vialo.
The product contains approximately 175 IU/ ml antithrombin alfa when reconstituted with 10 ml of Sterile Water for Injection (WFI).
Zdravilo vsebuje približno 175 i. e. / ml antitrombina alfa, ko ga rekonstituiramo z 10 ml sterilne vode za injekcije.
Antithrombin alfa is a recombinant form of human antithrombin and is produced by recombinant DNA technology in the milk of transgenic goats.
Antitrombin alfa je rekombinantna oblika humanega antitrombina, ki se proizvaja z rekombinantno DNA tehnologijo v mleku transgenskih koz.
The potency (IU) is determined using the European Pharmacopoeial chromogenic assay.
Jakost (i. e.) se doloca s pomocjo kromogenega testa po Evropski farmakopeji.
The specific activity of ATryn is approximately 7 IU/ mg protein.
Specificna aktivnost zdravila ATryn je približno 7 i. e. / mg beljakovin.
For a full list of excipients, see section 6.1.
Za celoten seznam pomožnih snovi glejte 6. 1.
Powder for solution for infusion.
Prašek za pripravo raztopine za infundiranje.
White to off-white powder.
Bel do sivkastobel prašek.
ATryn is indicated for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency.
Zdravilo ATryn se uporablja za profilakso venskega tromboembolizma pri operacijah bolnikov s prirojenim pomanjkanjem antitrombina.
ATryn is normally given in association with heparin or low molecular weight heparin.
Zdravilo ATryn se obicajno uporablja v povezavi s heparinom ali heparinom z nizko molekularno maso.
4.2 Posology and method of administration
4. 2 Odmerjanje in nacin uporabe
Due to differences in pharmacokinetics of antithrombin alfa and plasma-derived antithrombin, treatment with ATryn should follow the specific dosing recommendations described below.
Zaradi razlike v farmakokinetiki antitrombina alfa in antitrombina, pridobljenega iz plazme, morate ob zdravljenju z zdravilom ATryn upoštevati natancna priporocila za odmerjanje, opisana spodaj.
In the treatment of congenital antithrombin deficiency, the dosage and duration of treatment should be individualised for each patient taking into account the family history with regard to thromboembolic events, the actual clinical risk factors, and the laboratory assessment.
Pri zdravljenju prirojenega pomanjkanja antitrombina je treba odmerek in trajanje zdravljenja prilagoditi posameznemu bolniku ob upoštevanju družinske anamneze, povezane s tromboembolijo, ter upoštevanju dejanskih dejavnikov klinicnega tveganja in laboratorijske ocene.
The number of units of antithrombin alfa administered is expressed in International Units (IU), which is related to the current WHO standard for antithrombin concentrate.
Število uporabljenih enot antitrombina alfa je izraženo v mednarodnih enotah (i. e.), kar se nanaša na trenutni standard WHO za koncentrat antitrombina.
Antithrombin (AT) activity in plasma is expressed either as a percentage (relative to human plasma) or in International Units (relative to the International Standard for antithrombin in plasma).
Aktivnost antitrombina (AT) v plazmi je izražena kot odstotek (glede na cloveško plazmo) ali kot mednarodne enote (glede na mednarodni standard za vsebnost antitrombina v plazmi).
One International Unit (IU) of antithrombin activity is equivalent to that quantity of antithrombin in one ml of normal human plasma.
Ena mednarodna enota (i. e.) aktivnosti antitrombina je enaka kolicini antitrombina v enem ml obicajne cloveške plazme.
The calculation of the required dosage of antithrombin alfa is based on pre-treatment plasma antithrombin activity and body weight.
Izracun potrebnega odmerka antitrombina alfa temelji na aktivnosti antitrombina v plazmi pred zdravljenjem in telesni masi.
2 The therapeutic goal of treatment with ATryn is to increase to, and maintain antithrombin activity between 80 – 120% (0.8 – 1.2 IU/ ml) for the duration of treatment.
2 Terapevtski namen zdravljenja z zdravilom ATryn je povecati in vzdrževati aktivnost antitrombina med 80 – 120% (0, 8 – 1, 2 i. e. / ml) v casu zdravljenja.
Initial treatment starts with a loading dose of ATryn targeting an antithrombin activity level of 100%.
Zacetno zdravljenje se zacne z odmerkom zdravila ATryn, ki dviguje raven aktivnosti antitrombina proti 100%.
This initial loading dose is based on body weight and on the pretreatment antithrombin activity level.
Zacetni odmerek se doloci glede na telesno maso in raven aktivnosti antitrombina pred zdravljenjem.
The required loading dose is determined using the following formula:
Potrebni zacetni odmerek dolocite z uporabo te formule:
Loading Dose (IU) = [(100 – patient’ s pre -treatment AT activity level in%) / 2.28] x Body Weight in kg
Zacetni odmerek (i. e.) = [(100 – raven aktivnosti antitrombina pri bolniku pred zdravljenjem v%) / 2, 28] x telesna masa v kilogramih
The usual loading dose in surgical patients (baseline AT activity 50%, bodyweight 75 kg) with congenital antithrombin deficiency in clinical risk situations is 20-25 IU/ kg bodyweight.
Obicajni zacetni odmerek pri operiranih bolnikih (osnovna aktivnost antitrombina 50%, telesna masa 75 kg) s prirojenim pomanjkanjem antitrombina v klinicno nevarnih razmerah znaša 20- 25 i. e. / kg telesne teže.
The loading dose should be given as a 15 minute infusion immediately followed by initiation of the maintenance infusion.
Zacetni odmerek je treba dati kot 15 minut trajajoco infuzijo, kateri takoj sledi vzdrževalna infuzija.
The required maintenance dose for surgical patients is given as a continuous infusion and is determined using the following formula:
Potrebni vzdrževalni odmerek pri operiranih bolnikih se daje kot neprekinjena infuzija, doloca pa se s to formulo:
Maintenance Dose (IU/ hour) = [(100 – patient’ s pre -treatment AT activity level in%) / 10.22] x Body Weight in kg
Vzdrževalni odmerek (i. e. / uro) = [(100 – raven aktivnosti antitrombina pri bolniku pred zdravljenjem v%) / 10, 22] x telesna mase v kilogramih
The usual maintenance dose in surgical patients with congenital antithrombin deficiency in clinical risk situations is 4-5 IU/ kg/ h.
Obicajni vzdrževalni odmerek pri operiranih bolnikih s prirojenim pomanjkanjem antitrombina v klinicno nevarnih razmerah znaša 4- 5 i. e. / kg/ h.
During consumptive states (e. g. major surgery, concomitant use of heparin) the actual dose may be higher.
Med vecjo porabo (npr. vecje operacije, hkratna uporaba heparina) je lahko dejanski odmerek višji.
See therapeutic monitoring and dose adjustment recommendations below.
Spodaj si oglejte terapevtsko spremljanje in priporocila za prilagajanje odmerka.